Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Patent Office (EPO) has revoked Bayer Pharma's formulation patent for contraceptives Yasmin, Yasminelle and YAZ (EP 1214076 - micronization).
Subscribe to our email newsletter
The products are based on the hormones ethinylestradiol (estrogen) and drospirenone.
The EPO’s decision was backed by an appeal from Hexal (Sandoz) which was filed in 2006 against Bayer Pharma.
Bayer HealthCare Pharmaceuticals Strategic Marketing General Medicine head Flemming Ornskov said they are disappointed by the decision that the European Patent Office didn’t concur with our legal opinion.
"Our late-stage pipeline includes a new hormonal intrauterine contraceptive (LCS) and a contraceptive patch," Ornskov said.